Mario Santiago
Concepts (400)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Friend murine leukemia virus | 17 | 2021 | 31 | 5.730 |
Why?
| | Retroviridae Infections | 21 | 2024 | 47 | 5.200 |
Why?
| | Cytidine Deaminase | 21 | 2024 | 59 | 5.020 |
Why?
| | HIV-1 | 31 | 2026 | 895 | 3.660 |
Why?
| | Virus Replication | 19 | 2024 | 529 | 2.320 |
Why?
| | Antibodies, Neutralizing | 10 | 2022 | 340 | 2.230 |
Why?
| | HIV Infections | 23 | 2026 | 3079 | 2.050 |
Why?
| | Simian Immunodeficiency Virus | 19 | 2015 | 92 | 1.790 |
Why?
| | Interferon-alpha | 7 | 2020 | 197 | 1.790 |
Why?
| | Antiviral Agents | 9 | 2022 | 767 | 1.740 |
Why?
| | Antibodies, Viral | 12 | 2022 | 672 | 1.630 |
Why?
| | Somatic Hypermutation, Immunoglobulin | 3 | 2022 | 19 | 1.610 |
Why?
| | Simian Acquired Immunodeficiency Syndrome | 11 | 2015 | 92 | 1.480 |
Why?
| | CD4-Positive T-Lymphocytes | 12 | 2026 | 1128 | 1.480 |
Why?
| | Antigens, CD | 5 | 2016 | 555 | 1.390 |
Why?
| | Tumor Virus Infections | 8 | 2024 | 49 | 1.390 |
Why?
| | Dendritic Cells | 5 | 2020 | 499 | 1.280 |
Why?
| | Gastrointestinal Tract | 3 | 2022 | 208 | 1.250 |
Why?
| | Adaptive Immunity | 3 | 2021 | 169 | 1.140 |
Why?
| | Immunity, Innate | 12 | 2024 | 846 | 1.110 |
Why?
| | Membrane Glycoproteins | 3 | 2016 | 496 | 1.030 |
Why?
| | T-Lymphocytes, Cytotoxic | 3 | 2026 | 177 | 1.030 |
Why?
| | Interferon Type I | 7 | 2022 | 145 | 1.020 |
Why?
| | Interferons | 3 | 2024 | 188 | 0.880 |
Why?
| | Pan troglodytes | 11 | 2009 | 63 | 0.850 |
Why?
| | SAM Domain and HD Domain-Containing Protein 1 | 2 | 2021 | 12 | 0.850 |
Why?
| | Mice, Inbred BALB C | 11 | 2024 | 1253 | 0.750 |
Why?
| | Immunoglobulin A | 2 | 2022 | 214 | 0.700 |
Why?
| | Animals | 63 | 2025 | 38030 | 0.670 |
Why?
| | Interferon-beta | 2 | 2020 | 92 | 0.670 |
Why?
| | Mice, Knockout | 13 | 2024 | 3119 | 0.670 |
Why?
| | B-Lymphocytes | 6 | 2023 | 876 | 0.620 |
Why?
| | Viral Load | 9 | 2021 | 518 | 0.620 |
Why?
| | Virion | 4 | 2016 | 111 | 0.600 |
Why?
| | Proteins | 6 | 2022 | 1021 | 0.580 |
Why?
| | CD8-Positive T-Lymphocytes | 8 | 2021 | 917 | 0.570 |
Why?
| | Mice | 28 | 2025 | 18329 | 0.570 |
Why?
| | Leukemia, Experimental | 4 | 2014 | 27 | 0.560 |
Why?
| | Killer Cells, Natural | 5 | 2016 | 467 | 0.560 |
Why?
| | Endogenous Retroviruses | 2 | 2024 | 38 | 0.550 |
Why?
| | Lipopolysaccharides | 1 | 2021 | 863 | 0.550 |
Why?
| | Mice, Inbred C57BL | 17 | 2025 | 5988 | 0.530 |
Why?
| | RNA, Viral | 9 | 2024 | 687 | 0.510 |
Why?
| | Enterobacteriaceae | 1 | 2017 | 43 | 0.500 |
Why?
| | Host-Pathogen Interactions | 5 | 2024 | 371 | 0.500 |
Why?
| | Receptor, Interferon alpha-beta | 3 | 2024 | 35 | 0.500 |
Why?
| | Immunity, Cellular | 2 | 2016 | 272 | 0.470 |
Why?
| | Bone Marrow Stromal Antigen 2 | 5 | 2016 | 11 | 0.470 |
Why?
| | Immunoglobulin Variable Region | 1 | 2015 | 80 | 0.450 |
Why?
| | Immunoglobulin Heavy Chains | 1 | 2015 | 85 | 0.440 |
Why?
| | Immunomodulation | 1 | 2016 | 101 | 0.440 |
Why?
| | Immunoglobulin Fc Fragments | 1 | 2015 | 41 | 0.430 |
Why?
| | Dysbiosis | 4 | 2022 | 187 | 0.420 |
Why?
| | Feces | 10 | 2017 | 513 | 0.420 |
Why?
| | Viremia | 6 | 2020 | 158 | 0.410 |
Why?
| | Signal Transduction | 6 | 2024 | 5221 | 0.410 |
Why?
| | Intestines | 1 | 2017 | 358 | 0.400 |
Why?
| | Virus Diseases | 3 | 2022 | 216 | 0.380 |
Why?
| | Endoribonucleases | 1 | 2013 | 80 | 0.380 |
Why?
| | Antibody Formation | 3 | 2017 | 294 | 0.370 |
Why?
| | Colon | 5 | 2024 | 304 | 0.350 |
Why?
| | Molecular Sequence Data | 15 | 2014 | 2929 | 0.340 |
Why?
| | Antibody Affinity | 1 | 2010 | 60 | 0.320 |
Why?
| | HIV Seropositivity | 2 | 2022 | 118 | 0.310 |
Why?
| | Spleen | 5 | 2018 | 508 | 0.310 |
Why?
| | Humans | 61 | 2026 | 144261 | 0.310 |
Why?
| | Retroviridae | 3 | 2023 | 101 | 0.310 |
Why?
| | Antigens, Helminth | 2 | 1999 | 16 | 0.300 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 5 | 2010 | 981 | 0.300 |
Why?
| | Cercocebus atys | 3 | 2006 | 6 | 0.300 |
Why?
| | HIV-2 | 3 | 2006 | 18 | 0.290 |
Why?
| | Schistosomiasis japonica | 2 | 1999 | 34 | 0.290 |
Why?
| | Base Sequence | 7 | 2015 | 2187 | 0.290 |
Why?
| | Intestinal Mucosa | 4 | 2019 | 676 | 0.290 |
Why?
| | Animals, Wild | 3 | 2005 | 61 | 0.280 |
Why?
| | Cells, Cultured | 10 | 2018 | 4146 | 0.280 |
Why?
| | Macaca mulatta | 5 | 2021 | 191 | 0.280 |
Why?
| | Interleukin-15 | 2 | 2021 | 97 | 0.280 |
Why?
| | Polymorphism, Single Nucleotide | 2 | 2016 | 2143 | 0.280 |
Why?
| | Lymphocyte Activation | 5 | 2017 | 1126 | 0.280 |
Why?
| | Lymphocytes | 2 | 2021 | 382 | 0.270 |
Why?
| | Antigen Presentation | 2 | 2021 | 205 | 0.270 |
Why?
| | Reverse Transcription | 2 | 2021 | 20 | 0.270 |
Why?
| | Ape Diseases | 3 | 2008 | 7 | 0.270 |
Why?
| | Immunity, Humoral | 2 | 2022 | 120 | 0.260 |
Why?
| | Disease Reservoirs | 2 | 2006 | 25 | 0.260 |
Why?
| | Gene Expression Profiling | 6 | 2024 | 1782 | 0.260 |
Why?
| | Gastrointestinal Microbiome | 5 | 2024 | 771 | 0.250 |
Why?
| | Flow Cytometry | 4 | 2017 | 1172 | 0.250 |
Why?
| | Immunity, Mucosal | 3 | 2020 | 98 | 0.240 |
Why?
| | Sequence Analysis, DNA | 5 | 2017 | 824 | 0.240 |
Why?
| | Papillomavirus Infections | 2 | 2022 | 345 | 0.230 |
Why?
| | Genetic Variation | 4 | 2015 | 982 | 0.220 |
Why?
| | Thymocytes | 1 | 2025 | 34 | 0.220 |
Why?
| | Immunoglobulin G | 4 | 2022 | 893 | 0.220 |
Why?
| | Glycogen Synthase Kinase 3 beta | 1 | 2025 | 72 | 0.220 |
Why?
| | Mammary Tumor Virus, Mouse | 1 | 2024 | 45 | 0.210 |
Why?
| | Frameshifting, Ribosomal | 1 | 2024 | 9 | 0.210 |
Why?
| | HIV Long Terminal Repeat | 1 | 2024 | 11 | 0.210 |
Why?
| | Granzymes | 2 | 2022 | 49 | 0.210 |
Why?
| | Interferon-gamma | 2 | 2019 | 784 | 0.210 |
Why?
| | Phylogeny | 13 | 2017 | 1015 | 0.210 |
Why?
| | Spike Glycoprotein, Coronavirus | 2 | 2022 | 130 | 0.210 |
Why?
| | Immunoglobulin M | 4 | 2022 | 284 | 0.210 |
Why?
| | Bone Marrow Cells | 3 | 2016 | 320 | 0.210 |
Why?
| | Cercopithecus | 1 | 2003 | 3 | 0.210 |
Why?
| | Disease Models, Animal | 5 | 2018 | 4556 | 0.210 |
Why?
| | DNA Transposable Elements | 1 | 2024 | 121 | 0.200 |
Why?
| | Alternative Splicing | 2 | 2024 | 247 | 0.200 |
Why?
| | DNA, Viral | 3 | 2021 | 358 | 0.200 |
Why?
| | Exons | 1 | 2024 | 358 | 0.200 |
Why?
| | NF-kappa B | 2 | 2018 | 661 | 0.190 |
Why?
| | Receptors, Antigen, T-Cell, alpha-beta | 1 | 2025 | 331 | 0.190 |
Why?
| | Transcriptome | 2 | 2022 | 1044 | 0.190 |
Why?
| | Antibodies, Helminth | 2 | 1999 | 6 | 0.190 |
Why?
| | Recombination, Genetic | 4 | 2015 | 205 | 0.180 |
Why?
| | HEK293 Cells | 5 | 2024 | 744 | 0.180 |
Why?
| | Viral Regulatory and Accessory Proteins | 2 | 2016 | 27 | 0.180 |
Why?
| | Blood | 1 | 2022 | 109 | 0.170 |
Why?
| | Ruminococcus | 1 | 2021 | 8 | 0.170 |
Why?
| | T-Lymphocytes, Helper-Inducer | 2 | 2023 | 131 | 0.170 |
Why?
| | Acinetobacter | 1 | 2021 | 15 | 0.170 |
Why?
| | Acute Disease | 2 | 2016 | 1028 | 0.170 |
Why?
| | Peripheral Tolerance | 2 | 2020 | 14 | 0.170 |
Why?
| | RNA, Messenger | 3 | 2024 | 2829 | 0.170 |
Why?
| | Lymphopenia | 1 | 2021 | 65 | 0.170 |
Why?
| | Genome, Viral | 1 | 2003 | 218 | 0.170 |
Why?
| | Evolution, Molecular | 3 | 2016 | 513 | 0.160 |
Why?
| | Bacterial Translocation | 2 | 2019 | 52 | 0.160 |
Why?
| | Male | 22 | 2024 | 72035 | 0.160 |
Why?
| | Interferon-Induced Helicase, IFIH1 | 1 | 2020 | 19 | 0.160 |
Why?
| | Picornaviridae | 1 | 2020 | 18 | 0.160 |
Why?
| | Specimen Handling | 1 | 2022 | 185 | 0.160 |
Why?
| | Tropomyosin | 1 | 1999 | 11 | 0.160 |
Why?
| | Female | 24 | 2024 | 77976 | 0.160 |
Why?
| | Immunologic Factors | 2 | 2019 | 255 | 0.150 |
Why?
| | Salmonella typhimurium | 1 | 2021 | 190 | 0.150 |
Why?
| | Genotype | 3 | 2013 | 1833 | 0.150 |
Why?
| | Cell Line | 6 | 2020 | 2879 | 0.150 |
Why?
| | Keratinocytes | 2 | 2018 | 248 | 0.150 |
Why?
| | Interleukin-2 | 2 | 2022 | 437 | 0.150 |
Why?
| | nef Gene Products, Human Immunodeficiency Virus | 3 | 2016 | 19 | 0.150 |
Why?
| | Helminth Proteins | 1 | 1999 | 24 | 0.150 |
Why?
| | Gram-Positive Bacteria | 1 | 2019 | 47 | 0.150 |
Why?
| | Sialic Acid Binding Ig-like Lectin 1 | 1 | 2018 | 11 | 0.140 |
Why?
| | Immunologic Memory | 1 | 2021 | 366 | 0.140 |
Why?
| | GPI-Linked Proteins | 2 | 2016 | 80 | 0.140 |
Why?
| | Lymph Nodes | 3 | 2018 | 502 | 0.140 |
Why?
| | Lectins | 1 | 2018 | 44 | 0.140 |
Why?
| | Protective Agents | 1 | 2018 | 42 | 0.140 |
Why?
| | Gram-Negative Bacteria | 1 | 2019 | 81 | 0.140 |
Why?
| | Sexually Transmitted Diseases, Viral | 1 | 1998 | 11 | 0.140 |
Why?
| | Papillomavirus E7 Proteins | 1 | 2018 | 11 | 0.140 |
Why?
| | Cullin Proteins | 1 | 2018 | 13 | 0.140 |
Why?
| | Human papillomavirus 16 | 1 | 2018 | 27 | 0.140 |
Why?
| | HIV | 3 | 2018 | 248 | 0.140 |
Why?
| | Human Immunodeficiency Virus Proteins | 2 | 2016 | 6 | 0.130 |
Why?
| | APOBEC-1 Deaminase | 2 | 2014 | 5 | 0.130 |
Why?
| | Viral Tropism | 1 | 2017 | 36 | 0.130 |
Why?
| | Interleukins | 1 | 2019 | 248 | 0.130 |
Why?
| | Proteolysis | 1 | 2018 | 173 | 0.130 |
Why?
| | Allergens | 1 | 2020 | 384 | 0.130 |
Why?
| | Proteome | 1 | 2022 | 514 | 0.130 |
Why?
| | Immunoglobulin E | 1 | 1999 | 315 | 0.130 |
Why?
| | Parvoviridae Infections | 1 | 2016 | 12 | 0.120 |
Why?
| | Toll-Like Receptor 7 | 1 | 2016 | 43 | 0.120 |
Why?
| | Disease Resistance | 1 | 2016 | 29 | 0.120 |
Why?
| | Influenza, Human | 1 | 2022 | 615 | 0.120 |
Why?
| | Mutagenesis, Insertional | 1 | 2016 | 63 | 0.120 |
Why?
| | Leukocytes, Mononuclear | 4 | 2024 | 573 | 0.120 |
Why?
| | Case-Control Studies | 2 | 2022 | 3592 | 0.120 |
Why?
| | Interleukin-12 | 1 | 2016 | 117 | 0.120 |
Why?
| | Butyrates | 1 | 2017 | 67 | 0.120 |
Why?
| | Amino Acid Sequence | 6 | 2016 | 2154 | 0.120 |
Why?
| | Primates | 2 | 2015 | 131 | 0.120 |
Why?
| | B7-1 Antigen | 1 | 2016 | 55 | 0.120 |
Why?
| | Biological Products | 1 | 2019 | 251 | 0.120 |
Why?
| | Lymphoid Tissue | 2 | 2020 | 80 | 0.120 |
Why?
| | PTEN Phosphohydrolase | 1 | 2017 | 164 | 0.120 |
Why?
| | NIH 3T3 Cells | 1 | 2016 | 148 | 0.120 |
Why?
| | Gene Products, nef | 2 | 2006 | 12 | 0.120 |
Why?
| | Antibody Diversity | 1 | 2015 | 16 | 0.110 |
Why?
| | Phenotype | 2 | 2016 | 3157 | 0.110 |
Why?
| | Major Histocompatibility Complex | 1 | 2016 | 229 | 0.110 |
Why?
| | Cell Proliferation | 2 | 2019 | 2494 | 0.110 |
Why?
| | Toll-Like Receptor 3 | 1 | 2014 | 28 | 0.110 |
Why?
| | Colobus | 1 | 2014 | 3 | 0.110 |
Why?
| | Endocytosis | 1 | 2016 | 168 | 0.110 |
Why?
| | Histones | 1 | 2020 | 668 | 0.110 |
Why?
| | Gene Expression Regulation | 4 | 2024 | 2603 | 0.110 |
Why?
| | T-Lymphocytes, Regulatory | 1 | 2017 | 388 | 0.110 |
Why?
| | Bacteria | 2 | 2022 | 889 | 0.110 |
Why?
| | Autoimmunity | 1 | 2020 | 924 | 0.100 |
Why?
| | Cote d'Ivoire | 2 | 2005 | 8 | 0.100 |
Why?
| | Immunization | 2 | 2020 | 374 | 0.100 |
Why?
| | Cloning, Molecular | 3 | 2013 | 539 | 0.100 |
Why?
| | Papillomaviridae | 1 | 2014 | 115 | 0.100 |
Why?
| | env Gene Products, Human Immunodeficiency Virus | 1 | 2013 | 14 | 0.100 |
Why?
| | Gene Frequency | 1 | 2015 | 481 | 0.100 |
Why?
| | Biological Evolution | 2 | 2012 | 488 | 0.100 |
Why?
| | Germinal Center | 1 | 2014 | 67 | 0.100 |
Why?
| | APOBEC Deaminases | 2 | 2024 | 6 | 0.100 |
Why?
| | Prevalence | 4 | 2006 | 2815 | 0.100 |
Why?
| | Neoplasms | 2 | 2022 | 2870 | 0.100 |
Why?
| | Virus Integration | 1 | 2013 | 69 | 0.100 |
Why?
| | T-Lymphocyte Subsets | 1 | 2016 | 415 | 0.100 |
Why?
| | Tanzania | 2 | 2003 | 62 | 0.090 |
Why?
| | DNA Damage | 1 | 2015 | 428 | 0.090 |
Why?
| | Uganda | 2 | 2003 | 91 | 0.090 |
Why?
| | Urine | 2 | 2003 | 62 | 0.090 |
Why?
| | Amino Acids | 1 | 2016 | 521 | 0.090 |
Why?
| | Inbreeding | 1 | 2012 | 20 | 0.090 |
Why?
| | Cell Membrane | 1 | 2016 | 706 | 0.090 |
Why?
| | Down-Regulation | 3 | 2018 | 627 | 0.090 |
Why?
| | Adult | 10 | 2024 | 40262 | 0.090 |
Why?
| | High-Throughput Nucleotide Sequencing | 1 | 2015 | 549 | 0.090 |
Why?
| | Neutralization Tests | 2 | 2008 | 76 | 0.090 |
Why?
| | Carcinogenesis | 2 | 2024 | 229 | 0.090 |
Why?
| | Mice, Inbred Strains | 1 | 2012 | 397 | 0.090 |
Why?
| | Mutation | 3 | 2024 | 4085 | 0.080 |
Why?
| | Philippines | 3 | 2001 | 52 | 0.080 |
Why?
| | Middle Aged | 8 | 2024 | 35762 | 0.080 |
Why?
| | DNA Primers | 3 | 2013 | 511 | 0.080 |
Why?
| | B-Cell Activation Factor Receptor | 1 | 2010 | 12 | 0.080 |
Why?
| | Protein Isoforms | 2 | 2024 | 402 | 0.080 |
Why?
| | vif Gene Products, Human Immunodeficiency Virus | 1 | 2010 | 3 | 0.080 |
Why?
| | Leukemia Virus, Murine | 1 | 2010 | 17 | 0.080 |
Why?
| | CD4 Antigens | 3 | 2006 | 139 | 0.080 |
Why?
| | Phenylacetates | 1 | 2010 | 10 | 0.080 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 3 | 2016 | 850 | 0.080 |
Why?
| | Cytosine Deaminase | 1 | 2010 | 15 | 0.080 |
Why?
| | Nitrophenols | 1 | 2010 | 29 | 0.080 |
Why?
| | Gene Products, gag | 1 | 2010 | 38 | 0.080 |
Why?
| | Young Adult | 4 | 2020 | 13990 | 0.080 |
Why?
| | Plasma | 1 | 2011 | 224 | 0.080 |
Why?
| | Apoptosis | 3 | 2014 | 2430 | 0.080 |
Why?
| | Lentivirus | 2 | 2013 | 60 | 0.070 |
Why?
| | Escherichia coli | 1 | 2014 | 852 | 0.070 |
Why?
| | T-Lymphocytes | 3 | 2020 | 1982 | 0.070 |
Why?
| | Sequence Analysis, RNA | 1 | 2011 | 442 | 0.070 |
Why?
| | Retroelements | 2 | 2024 | 51 | 0.070 |
Why?
| | Molecular Epidemiology | 2 | 2006 | 73 | 0.070 |
Why?
| | Simian foamy virus | 1 | 2008 | 3 | 0.070 |
Why?
| | Sequence Homology, Amino Acid | 3 | 2011 | 396 | 0.070 |
Why?
| | Receptors, Antigen, B-Cell | 2 | 2020 | 134 | 0.070 |
Why?
| | Phosphorylation | 2 | 2025 | 1732 | 0.060 |
Why?
| | Chromosome Mapping | 1 | 2008 | 509 | 0.060 |
Why?
| | Promoter Regions, Genetic | 1 | 2011 | 1255 | 0.060 |
Why?
| | Immunotherapy | 2 | 2023 | 652 | 0.060 |
Why?
| | Inflammation | 1 | 2018 | 2877 | 0.060 |
Why?
| | Lentiviruses, Primate | 1 | 2006 | 12 | 0.060 |
Why?
| | Cross-Sectional Studies | 4 | 2018 | 5813 | 0.060 |
Why?
| | Genes, env | 1 | 2005 | 5 | 0.060 |
Why?
| | Genes, gag | 1 | 2005 | 4 | 0.060 |
Why?
| | Blotting, Western | 3 | 2010 | 1187 | 0.060 |
Why?
| | Social Dominance | 1 | 2005 | 18 | 0.060 |
Why?
| | V(D)J Recombination | 1 | 2025 | 8 | 0.060 |
Why?
| | Disease Transmission, Infectious | 1 | 2005 | 69 | 0.060 |
Why?
| | Heterogeneous-Nuclear Ribonucleoproteins | 1 | 2024 | 18 | 0.050 |
Why?
| | RNA Transport | 1 | 2024 | 27 | 0.050 |
Why?
| | Jurkat Cells | 1 | 2024 | 114 | 0.050 |
Why?
| | Poliovirus Vaccine, Oral | 1 | 2004 | 25 | 0.050 |
Why?
| | Long Interspersed Nucleotide Elements | 1 | 2024 | 32 | 0.050 |
Why?
| | Cell Survival | 2 | 2019 | 1098 | 0.050 |
Why?
| | Infectious Disease Transmission, Vertical | 1 | 2005 | 187 | 0.050 |
Why?
| | Dependovirus | 2 | 2016 | 79 | 0.050 |
Why?
| | Endemic Diseases | 1 | 2003 | 33 | 0.050 |
Why?
| | Retroviridae Proteins | 1 | 2003 | 10 | 0.050 |
Why?
| | Time Factors | 1 | 2014 | 7155 | 0.050 |
Why?
| | Recombinant Proteins | 2 | 2018 | 1367 | 0.050 |
Why?
| | Mice, Transgenic | 2 | 2020 | 2182 | 0.050 |
Why?
| | Disease Outbreaks | 1 | 2006 | 422 | 0.050 |
Why?
| | Acquired Immunodeficiency Syndrome | 1 | 2004 | 231 | 0.050 |
Why?
| | Cytidine | 1 | 2022 | 9 | 0.050 |
Why?
| | Serine-Arginine Splicing Factors | 1 | 2022 | 26 | 0.050 |
Why?
| | Apolipoproteins | 1 | 2022 | 37 | 0.050 |
Why?
| | Polymerase Chain Reaction | 2 | 2002 | 1054 | 0.040 |
Why?
| | Wuchereria bancrofti | 1 | 2001 | 1 | 0.040 |
Why?
| | Filariasis | 1 | 2001 | 3 | 0.040 |
Why?
| | Protein Structure, Tertiary | 2 | 2014 | 862 | 0.040 |
Why?
| | Datasets as Topic | 1 | 2022 | 122 | 0.040 |
Why?
| | World Health Organization | 1 | 2022 | 103 | 0.040 |
Why?
| | DNA, Helminth | 1 | 2001 | 26 | 0.040 |
Why?
| | Immunoblotting | 1 | 2002 | 300 | 0.040 |
Why?
| | Lymphocyte Depletion | 1 | 2021 | 132 | 0.040 |
Why?
| | Hemagglutination | 1 | 2020 | 7 | 0.040 |
Why?
| | Macrophages | 2 | 2018 | 1510 | 0.040 |
Why?
| | Antibodies | 1 | 2022 | 401 | 0.040 |
Why?
| | COS Cells | 1 | 2020 | 181 | 0.040 |
Why?
| | Snails | 1 | 1999 | 37 | 0.040 |
Why?
| | Immune Evasion | 1 | 2020 | 64 | 0.040 |
Why?
| | Gene Library | 1 | 1999 | 126 | 0.040 |
Why?
| | Toll-Like Receptors | 1 | 2020 | 194 | 0.040 |
Why?
| | Recombinant Fusion Proteins | 2 | 2016 | 674 | 0.040 |
Why?
| | Erythroblasts | 1 | 2018 | 19 | 0.040 |
Why?
| | CD4 Lymphocyte Count | 2 | 2014 | 274 | 0.040 |
Why?
| | Nucleic Acid Heteroduplexes | 1 | 1998 | 9 | 0.040 |
Why?
| | Rabbits | 1 | 1999 | 648 | 0.040 |
Why?
| | Sex Work | 1 | 1998 | 22 | 0.030 |
Why?
| | Interferon Regulatory Factor-7 | 1 | 2018 | 6 | 0.030 |
Why?
| | Sendai virus | 1 | 2018 | 6 | 0.030 |
Why?
| | Sensitivity and Specificity | 1 | 2003 | 1983 | 0.030 |
Why?
| | NF-KappaB Inhibitor alpha | 1 | 2018 | 49 | 0.030 |
Why?
| | THP-1 Cells | 1 | 2018 | 20 | 0.030 |
Why?
| | I-kappa B Kinase | 1 | 2018 | 51 | 0.030 |
Why?
| | Enzyme Stability | 1 | 2018 | 72 | 0.030 |
Why?
| | Cell Line, Transformed | 1 | 2018 | 140 | 0.030 |
Why?
| | Antigenic Variation | 1 | 1997 | 11 | 0.030 |
Why?
| | Disease Progression | 2 | 2016 | 2840 | 0.030 |
Why?
| | Antigens, Protozoan | 1 | 1997 | 32 | 0.030 |
Why?
| | Inpatients | 1 | 2022 | 542 | 0.030 |
Why?
| | Autoantigens | 1 | 2020 | 429 | 0.030 |
Why?
| | Phosphatidylinositol-3,4,5-Trisphosphate 5-Phosphatases | 1 | 2017 | 15 | 0.030 |
Why?
| | HIV Envelope Protein gp120 | 1 | 2017 | 55 | 0.030 |
Why?
| | Palatine Tonsil | 1 | 2017 | 55 | 0.030 |
Why?
| | Anti-Retroviral Agents | 1 | 2019 | 240 | 0.030 |
Why?
| | Cross Reactions | 1 | 2017 | 130 | 0.030 |
Why?
| | Plasmodium falciparum | 1 | 1997 | 39 | 0.030 |
Why?
| | Malaria, Falciparum | 1 | 1997 | 33 | 0.030 |
Why?
| | Ki-67 Antigen | 1 | 2017 | 117 | 0.030 |
Why?
| | Antigens, Surface | 1 | 1997 | 157 | 0.030 |
Why?
| | Gene Silencing | 1 | 2018 | 205 | 0.030 |
Why?
| | Interleukin-1beta | 1 | 2019 | 395 | 0.030 |
Why?
| | DNA, Ribosomal | 1 | 2017 | 94 | 0.030 |
Why?
| | Protozoan Proteins | 1 | 1997 | 93 | 0.030 |
Why?
| | Receptors, CXCR4 | 1 | 2017 | 91 | 0.030 |
Why?
| | APOBEC-3G Deaminase | 1 | 2016 | 5 | 0.030 |
Why?
| | Myxovirus Resistance Proteins | 1 | 2016 | 13 | 0.030 |
Why?
| | Models, Biological | 1 | 2004 | 1820 | 0.030 |
Why?
| | Peptides | 1 | 2022 | 995 | 0.030 |
Why?
| | Sequence Deletion | 1 | 2016 | 193 | 0.030 |
Why?
| | Amino Acid Motifs | 1 | 2016 | 224 | 0.030 |
Why?
| | Myeloid Differentiation Factor 88 | 1 | 2016 | 114 | 0.030 |
Why?
| | DNA, Mitochondrial | 2 | 2008 | 210 | 0.030 |
Why?
| | DNA, Bacterial | 1 | 2017 | 342 | 0.030 |
Why?
| | Cluster Analysis | 1 | 2017 | 519 | 0.030 |
Why?
| | Imidazoles | 1 | 2016 | 254 | 0.030 |
Why?
| | Protein Processing, Post-Translational | 1 | 2018 | 477 | 0.030 |
Why?
| | Receptors, CCR7 | 1 | 2014 | 31 | 0.030 |
Why?
| | Receptors, CXCR5 | 1 | 2014 | 27 | 0.030 |
Why?
| | Protein Transport | 1 | 2016 | 441 | 0.030 |
Why?
| | Biopsy | 1 | 2018 | 1075 | 0.030 |
Why?
| | Cervix Uteri | 1 | 2014 | 50 | 0.030 |
Why?
| | RNA, Ribosomal, 16S | 1 | 2017 | 558 | 0.030 |
Why?
| | Sexual Behavior | 1 | 1998 | 484 | 0.030 |
Why?
| | Antigens, Viral | 1 | 2014 | 182 | 0.030 |
Why?
| | Viral Proteins | 1 | 2016 | 355 | 0.030 |
Why?
| | Vaccines | 1 | 1999 | 389 | 0.030 |
Why?
| | Gene Expression Regulation, Enzymologic | 1 | 2014 | 269 | 0.020 |
Why?
| | Caspase 1 | 1 | 2014 | 148 | 0.020 |
Why?
| | Genetic Engineering | 1 | 2013 | 93 | 0.020 |
Why?
| | Mucous Membrane | 1 | 2014 | 127 | 0.020 |
Why?
| | Sequence Alignment | 1 | 2013 | 366 | 0.020 |
Why?
| | Antibodies, Monoclonal | 1 | 2020 | 1519 | 0.020 |
Why?
| | In Vitro Techniques | 1 | 2014 | 1047 | 0.020 |
Why?
| | Cytokines | 1 | 2019 | 2061 | 0.020 |
Why?
| | HIV Reverse Transcriptase | 1 | 2010 | 31 | 0.020 |
Why?
| | Glycosylation | 1 | 2010 | 172 | 0.020 |
Why?
| | Cell Movement | 1 | 2014 | 965 | 0.020 |
Why?
| | L-Selectin | 1 | 2009 | 27 | 0.020 |
Why?
| | HIV Core Protein p24 | 1 | 2009 | 32 | 0.020 |
Why?
| | Autoantibodies | 1 | 2017 | 1497 | 0.020 |
Why?
| | Microbiota | 1 | 2017 | 781 | 0.020 |
Why?
| | DNA Replication | 1 | 2010 | 250 | 0.020 |
Why?
| | Africa, Central | 1 | 2008 | 6 | 0.020 |
Why?
| | Genetics, Microbial | 1 | 2008 | 11 | 0.020 |
Why?
| | HLA-DR Antigens | 1 | 2009 | 220 | 0.020 |
Why?
| | Child | 2 | 2017 | 22537 | 0.020 |
Why?
| | Aged | 2 | 2017 | 25850 | 0.020 |
Why?
| | Infant, Newborn | 1 | 1999 | 6424 | 0.020 |
Why?
| | Gene Products, pol | 1 | 2007 | 6 | 0.020 |
Why?
| | Consensus Sequence | 1 | 2007 | 74 | 0.020 |
Why?
| | Ecology | 1 | 2008 | 121 | 0.020 |
Why?
| | Aged, 80 and over | 1 | 1999 | 8243 | 0.020 |
Why?
| | Adolescent | 2 | 2012 | 22281 | 0.020 |
Why?
| | Receptor-CD3 Complex, Antigen, T-Cell | 1 | 2006 | 9 | 0.020 |
Why?
| | Cameroon | 1 | 2006 | 7 | 0.020 |
Why?
| | HIV Antibodies | 1 | 2006 | 60 | 0.010 |
Why?
| | Prospective Studies | 1 | 1998 | 7970 | 0.010 |
Why?
| | Infant | 1 | 1999 | 10022 | 0.010 |
Why?
| | p21-Activated Kinases | 1 | 2004 | 14 | 0.010 |
Why?
| | Haplotypes | 1 | 2006 | 490 | 0.010 |
Why?
| | Africa, Western | 1 | 2004 | 21 | 0.010 |
Why?
| | CD28 Antigens | 1 | 2004 | 58 | 0.010 |
Why?
| | Child, Preschool | 1 | 1999 | 11774 | 0.010 |
Why?
| | Mutagenesis, Site-Directed | 1 | 2005 | 381 | 0.010 |
Why?
| | Protein Binding | 1 | 2010 | 2270 | 0.010 |
Why?
| | Risk Factors | 1 | 1998 | 10699 | 0.010 |
Why?
| | Green Fluorescent Proteins | 1 | 2005 | 405 | 0.010 |
Why?
| | HeLa Cells | 1 | 2005 | 650 | 0.010 |
Why?
| | Ecosystem | 1 | 2008 | 589 | 0.010 |
Why?
| | Transfection | 1 | 2005 | 938 | 0.010 |
Why?
| | Histocompatibility Antigens Class II | 1 | 2004 | 364 | 0.010 |
Why?
| | Deoxyribonucleases, Type II Site-Specific | 1 | 2001 | 13 | 0.010 |
Why?
| | Africa | 1 | 2001 | 114 | 0.010 |
Why?
| | Malaria Vaccines | 1 | 1997 | 11 | 0.010 |
Why?
| | DNA, Protozoan | 1 | 1997 | 32 | 0.010 |
Why?
| | Point Mutation | 1 | 1997 | 243 | 0.010 |
Why?
| | Reproducibility of Results | 1 | 2004 | 3403 | 0.010 |
Why?
| | Epitopes | 1 | 1997 | 485 | 0.010 |
Why?
|
|
Santiago's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|